BS_GS1KR5PK
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 10.64388961892247
- age_years
- 3.345
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.555
- E2F_TARGETS+0.378
- G2M_CHECKPOINT+0.368
- MYC_TARGETS_V1+0.335
- SPERMATOGENESIS+0.310
- KRAS_SIGNALING_DN+0.194
- PANCREAS_BETA_CELLS+0.179
- UNFOLDED_PROTEIN_RESPONSE+0.091
- MTORC1_SIGNALING+0.064
- MITOTIC_SPINDLE-0.028
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.632
- INTERFERON_GAMMA_RESPONSE-0.584
- IL6_JAK_STAT3_SIGNALING-0.571
- TGF_BETA_SIGNALING-0.556
- NOTCH_SIGNALING-0.544
- ALLOGRAFT_REJECTION-0.501
- ANGIOGENESIS-0.488
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- COAGULATION-0.428
- INFLAMMATORY_RESPONSE-0.426
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_W644VEVE | medulloblastoma | — | 0.947 |
| 2 | BS_YEB88D32 | medulloblastoma | — | 0.944 |
| 3 | SRR5088911 | — | — | 0.938 |
| 4 | BS_ZXYDSBM9 | medulloblastoma | — | 0.936 |
| 5 | BS_9PB3XH5D | medulloblastoma | — | 0.932 |
| 6 | BS_1BWP5MCT | medulloblastoma | — | 0.932 |
| 7 | BS_W9AT0MR7 | medulloblastoma | — | 0.930 |
| 8 | BS_5VQP0E6K | medulloblastoma | — | 0.930 |
| 9 | BS_09Z7TC35 | medulloblastoma | — | 0.929 |
| 10 | BS_3F5PR9GS | medulloblastoma | — | 0.929 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.555 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.378 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.368 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.335 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.194 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.179 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.091 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.064 | Inavolisib | — uncovered |